MedTrace Logo

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

NCT00803894 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-06-17

No results posted yet for this study

Summary

The purpose of this study is to determine the transcriptional signature of Notch Inhibition by testing hair and blood samples on healthy male volunteers who have received MK0752 vs placebo for possible future biomarkers in the treatment of cancer or Alzheimers Disease

Conditions

  • Healthy

Interventions

DRUG

MK0752

Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.

DRUG

Comparator: MK0752.

Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.

DRUG

Comparator: Placebo

Single dose placebo capsules: there will be a 7-day washout period between treatments.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-01-31
Completion
2009-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803894 on ClinicalTrials.gov